How to: assess patient suitability for unlicensed phage therapy in the United Kingdom.

IF 10.9 1区 医学 Q1 INFECTIOUS DISEASES
Clinical Microbiology and Infection Pub Date : 2025-01-01 Epub Date: 2024-08-05 DOI:10.1016/j.cmi.2024.07.022
Joshua D Jones, Helen J Stacey, John W Kennedy, Maya Merabishvilli, Melissa E K Haines, Oliver Blocker, Kumara Dharmasena, Andrew Gordon, Stuart A Hamilton, Ila Aggarwal, John Nagy, Don S Urquhart, Lesley M L Hall, Matthew J Young, Gordon MacGregor, Ross J Langley, Christine Peters, Daniela I Munteanu
{"title":"How to: assess patient suitability for unlicensed phage therapy in the United Kingdom.","authors":"Joshua D Jones, Helen J Stacey, John W Kennedy, Maya Merabishvilli, Melissa E K Haines, Oliver Blocker, Kumara Dharmasena, Andrew Gordon, Stuart A Hamilton, Ila Aggarwal, John Nagy, Don S Urquhart, Lesley M L Hall, Matthew J Young, Gordon MacGregor, Ross J Langley, Christine Peters, Daniela I Munteanu","doi":"10.1016/j.cmi.2024.07.022","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Bacteriophage (phage) therapy is a promising alternative antimicrobial approach that has the potential to transform the way we treat bacterial infections. The antibiotic resistance crisis is driving renewed interest in phage therapy. There are currently no licensed phage therapy medicinal products and phage therapy is used in small but growing patient numbers on an unlicensed basis.</p><p><strong>Objectives: </strong>This article provides guidelines on the assessment of patient suitability for unlicensed phage therapy for clinicians in the United Kingdom.</p><p><strong>Sources: </strong>This article builds on Health Improvement Scotland's recommendation for the consideration of phage therapy in difficult-to-treat infections and the experience of the author group, who have collectively assessed the suitability of 30 patients for phage therapy.</p><p><strong>Content: </strong>In the United Kingdom, unlicenced medicines, including phages, may be considered to meet special clinical needs. The use of unlicenced medicines is governed by national legislation and local National Health Service trust policies. Phages can be used in any National Health Service trust and decisions about suitability should be made through existing local clinical management pathways. This article sets out guidelines to support local clinical teams in the assessment of patient suitability for phage therapy. Clinical and microbiological considerations are presented, including allergy and pregnancy.</p><p><strong>Implications: </strong>The assessment of patient suitability for phage therapy is within the scope of local clinical teams. Local assessment through existing clinical management pathways will develop confidence and competence in phage therapy among clinical teams nationally and ensure timely patient care.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":"57-61"},"PeriodicalIF":10.9000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Microbiology and Infection","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cmi.2024.07.022","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Bacteriophage (phage) therapy is a promising alternative antimicrobial approach that has the potential to transform the way we treat bacterial infections. The antibiotic resistance crisis is driving renewed interest in phage therapy. There are currently no licensed phage therapy medicinal products and phage therapy is used in small but growing patient numbers on an unlicensed basis.

Objectives: This article provides guidelines on the assessment of patient suitability for unlicensed phage therapy for clinicians in the United Kingdom.

Sources: This article builds on Health Improvement Scotland's recommendation for the consideration of phage therapy in difficult-to-treat infections and the experience of the author group, who have collectively assessed the suitability of 30 patients for phage therapy.

Content: In the United Kingdom, unlicenced medicines, including phages, may be considered to meet special clinical needs. The use of unlicenced medicines is governed by national legislation and local National Health Service trust policies. Phages can be used in any National Health Service trust and decisions about suitability should be made through existing local clinical management pathways. This article sets out guidelines to support local clinical teams in the assessment of patient suitability for phage therapy. Clinical and microbiological considerations are presented, including allergy and pregnancy.

Implications: The assessment of patient suitability for phage therapy is within the scope of local clinical teams. Local assessment through existing clinical management pathways will develop confidence and competence in phage therapy among clinical teams nationally and ensure timely patient care.

如何:在英国评估患者是否适合接受无证噬菌体疗法。
背景:噬菌体疗法是一种前景广阔的替代抗菌方法,有可能改变我们治疗细菌感染的方式。抗生素耐药性危机促使人们重新关注噬菌体疗法。目前还没有获得许可的噬菌体疗法药物产品,噬菌体疗法在未经许可的情况下使用的患者人数虽然不多,但在不断增加:本文为英国临床医生提供了评估患者是否适合接受无证噬菌体疗法的指南:本文基于苏格兰健康改善组织(Health Improvement Scotland)关于在难以治疗的感染中考虑使用噬菌体疗法的建议,以及作者小组的经验,他们曾共同评估了 30 名患者是否适合使用噬菌体疗法:在英国,包括噬菌体在内的无证药物可被考虑用于满足特殊的临床需求。无证药物的使用受国家法律和当地 NHS 信托基金会政策的制约。噬菌体可在任何 NHS 信托基金会中使用,应通过现有的地方临床管理途径决定是否适合使用。本文阐述了支持当地临床团队评估患者是否适合噬菌体疗法的指导原则。文中介绍了临床和微生物学方面的注意事项,包括过敏和妊娠。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
25.30
自引率
2.10%
发文量
441
审稿时长
2-4 weeks
期刊介绍: Clinical Microbiology and Infection (CMI) is a monthly journal published by the European Society of Clinical Microbiology and Infectious Diseases. It focuses on peer-reviewed papers covering basic and applied research in microbiology, infectious diseases, virology, parasitology, immunology, and epidemiology as they relate to therapy and diagnostics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信